Stroke and TIA: Comprehensive Study Notes

Stroke and TIA: Comprehensive Study Notes

  • Overview: TIA vs. stroke

    • TIA = a transient blockage that acts as a warning shot; symptoms resolve and blood flow returns, but risk factors persist.

    • Stroke = a persistent blockage or bleed causing ongoing brain injury if not treated.

    • TIAs are temporary ischemic events; they’re often a precursor to an actual stroke if risk factors aren’t managed.

    • In the talk, TIAs are described as temporary and exact same signs as a stroke, but duration distinguishes them.

    • Key statistic given: about 85% of people with a TIA will have a stroke within the next 30 days.

  • Signs and quick differentiation (FAST/BFAST concepts)

    • Slurred speech (dysarthria) and unilateral weakness are classic stroke signs.

    • Facial droop, arm weakness, leg weakness, speech disturbances, and balance/eye issues are all possible.

    • Vision changes can occur but retinal occlusion is more typical for certain visual presentations.

    • In stroke vs TIA, duration and reversibility are the main distinctions; signs point to brain areas involved.

  • Ischemic vs hemorrhagic stroke basics

    • Ischemic strokes are due to a blockage; hemorrhagic strokes due to bleeding.

    • Early mortality risk is higher when the backward supply to the brain is compromised (like basilar region) because there’s typically a single supply to that brain region.

    • Most strokes (in general practice) are ischemic, but hemorrhages require different urgent management.

  • Brain blood supply and localization cues

    • Circle of Willis and major arteries feed the brain; internal carotid arteries (ICAs) feed the circle of Willis and the front of the brain; posterior circulation involves the basilar system.

    • The right hemisphere stroke typically produces left-sided symptoms (contralateral control); the left hemisphere stroke typically produces right-sided symptoms.

    • An important rule: the back of the brain (posterior circulation) can produce different signs and may be associated with higher mortality if blood supply is compromised due to limited collateral flow (basilar area).

    • The location of deficits (frontal lobe vs parietal vs occipital vs brainstem) helps localize the stroke.

  • Anatomy quick refresher (key areas and functions)

    • Frontal lobe: motor control (motor strip).

    • Cerebellum: coordination (ataxia).

    • Parietal lobe: sensation and perception.

    • Occipital lobe: vision.

    • Wernicke’s area: receptive language (understanding).

    • Broca’s area: expressive language (speaking, producing words).

    • Brainstem/cerebellar connections modulate cranial nerve function and autonomic control.

  • Aphasia and language deficits

    • Broca’s (expressive) aphasia: can understand but cannot speak fluently; often phrases are telegraphic; associated with frontal lobe injury.

    • Wernicke’s (receptive) aphasia: speech fluent but nonsensical; unable to understand, often cannot follow commands.

    • Global aphasia: extensive damage; both comprehension and expression are poor.

    • Extinction/neglect: contralateral sensory neglect when attention to one side is reduced; tested by bilateral stimulation.

    • Language laterality: left hemisphere is dominant for language in most right-handed individuals; right hemisphere contributes to emotional control and some nonverbal aspects.

  • Motor, sensory, and coordination signs

    • Motor: weakness and/or drift on one side due to frontal lobe involvement.

    • Sensory: diminished sensation on one side; tested by comparing sides.

    • Limb ataxia: lack of coordination (often a cerebellar sign); not usually in the same limb as motor weakness unless there’s extensive involvement.

    • Cerebellar signs: truncal ataxia, gait disturbances; vertigo can be central (cerebellar) or peripheral (ear-related); acute onset vertigo always consider stroke until proven otherwise.

    • Facial palsy: one-sided weakness; the lower face shows contralateral weakness due to facial nerve innervation; forehead often has bilateral innervation, so upper face may be preserved on the affected side in facial weakness.

    • Gaze and eye movements: cranial nerves III, IV, VI tested via tracking, lateral gaze, and responses; changes here indicate brainstem or cortical involvement.

  • Visual and perceptual signs

    • Quadrantanopia or hemianopia can occur depending on lesion location (contralateral field deficits are common).

    • Cortical blindness can occur with occipital involvement; brain can sometimes fill in missing information, so patients may not notice field loss immediately.

    • Retinal occlusion vs cortical visual loss: signs help determine where the damage is in the visual pathway.

  • Vertigo and cranial nerve signs

    • Central vertigo (cerebellar) carries higher stroke risk and mortality than peripheral vertigo; acute onset vertigo warrants stroke workup.

    • Cranial nerve deficits provide a map to brainstem involvement (CN III–XII signs are used to localize lesions).

    • Doll’s eye phenomenon (oculocephalic reflex) and other brainstem signs help assess brainstem integrity.

  • Blood pressure, diabetes, and risk factors in stroke

    • Blood pressure elevations are common in acute stroke; management aims to avoid further injury while maintaining cerebral perfusion.

    • Chronic hypertension is a major risk factor for both ischemic and hemorrhagic strokes; tight, long-term control helps reduce risk.

    • Diabetes management: does not reverse earlier damage but helps prevent further progression and new events.

    • Dyslipidemia (LDL/HDL) management and lifestyle changes (e.g., Mediterranean diet) are emphasized for vascular health.

    • Smoking and substance use (including certain medications and hormonal therapies) increase stroke risk; birth control and hormones can elevate risk in some individuals.

  • Risk scoring and decision-making in the clinic

    • ABCD2 score (for TIA risk stratification):

    • A = Age ≥ 60 years → 1 point

    • B = Blood pressure at presentation ≥ 140/90 mmHg → 1 point

    • C = Clinical features: unilateral weakness (2 points); speech impairment without weakness (1 point)

    • D = Duration of symptoms: ≥ 60 minutes (2 points); 10–59 minutes (1 point)

    • Diabetes mellitus → 1 point

    • Total range: 0–7. Higher scores indicate greater short-term stroke risk; used to guide outpatient vs inpatient management and urgent workup.

    • CHADS2 (atrial fibrillation stroke risk):

    • C = Congestive heart failure (CHF)

    • H = Hypertension

    • A = Age ≥ 75 years

    • D = Diabetes mellitus

    • S = Stroke/TIA previously (2 points)

    • Total score guides anticoagulation decisions in AF patients (alternative scoring schemes like CHA2DS2-VASc exist in practice).

  • Neuro exam and how it’s taught (NIHSS-style testing in this lecture)

    • Core idea: assess both language and non-language functions; combine neuro signs to estimate stroke severity.

    • Level of consciousness: arousal, orientation, and ability to follow commands.

    • Best language and dysarthria: ability to understand and articulate; differentiate aphasia vs dysarthria.

    • Visual fields and gaze: visual neglect and cranial nerve function.

    • Facial palsy: symmetry of smile and eyebrow movement; lower face weakness often more pronounced than upper face.

    • Motor arm and leg: drift and strength in each limb; use standardized positioning (e.g., 45-degree arm hold, 30-degree leg hold).

    • Limb ataxia: aim to detect cerebellar coordination problems.

    • Sensory: compare sensation on both sides.

    • Best language: assess comprehension and expression with pictures and commands.

    • Extinction and neglect: bilateral stimulation to identify neglect on one side.

    • Finally, practice and interpretation: the examiner should adapt to patient ability and provide clear, one-step commands when needed; avoid overwhelming the patient and tailor to individual comprehension level.

    • Note on exam approach: use visual cues and simple instructions for patients with aphasia or cognitive impairment; test comprehension first, then execution.

  • Imaging, diagnosis, and escalation of care

    • Imaging modalities:

    • CT Head (non-contrast) to exclude hemorrhage; appears white on CT as bone and dense tissue.

    • CT Angiography (CTA) to assess vessel stenosis or occlusion; contrast-based.

    • MRI (diffusion-weighted imaging) for more sensitivity in some cases; not always available.

    • Ultrasound/duplex for carotid stenosis assessment.

    • Diffusion and perfusion concepts: diffusion CT/MRI can reveal early ischemic changes; perfusion imaging helps identify potentially salvageable tissue (penumbra).

    • Endovascular therapy: thrombectomy for large vessel occlusion (LVO) within a time window; effectiveness depends on tissue at risk (penumbra) and time since onset.

    • Tissue plasminogen activator (tPA) vs tenecteplase (TNK):

    • Alteplase (rt-PA) dosing commonly cited as a 0.9 mg/kg total dose (max 90 mg) with 10% given as a bolus and the remainder infused over 60 minutes; dosing and timing are time-critical.

    • Tenecteplase (TNK) is a single bolus, dose often cited around 0.25 mg/kg (max ~25 mg); quicker administration and certain practical advantages in some settings.

    • In rural or resource-limited areas, TNK can enable earlier reperfusion without the need for infusion setups.

    • Blood pressure management around thrombolysis

    • Before thrombolysis, blood pressure must be within target ranges (varies by protocol; common thresholds include systolic < 185 mmHg and diastolic < 110 mmHg to proceed with tPA in many guidelines).

    • After thrombolysis, blood pressure is typically kept below roughly 180/105 mmHg for the first 24 hours to minimize hemorrhagic risk while maintaining perfusion.

    • Antithrombotic therapy after ischemic stroke

    • Short-term dual antiplatelet therapy (e.g., aspirin + clopidogrel) may be used in specific subsets, but long-term dual therapy has bleeding risk.

    • Anticoagulants (warfarin or DOACs such as rivaroxaban, apixaban) are chosen based on cardioembolic sources (e.g., AF) rather than all ischemic strokes.

    • Antiplatelets, statins, and lifestyle

    • After ischemic stroke, many patients are discharged on antiplatelets (e.g., aspirin) and often a statin; dual therapy decisions depend on etiology and risk.

    • Analgesia and management of secondary issues (pain, anxiety, depression) improve outcomes; TCAs/SNRIs may be used for mood disorders post-stroke depending on patient tolerance and interactions.

  • Hemorrhagic stroke and intracranial pressure (ICP) concerns

    • Hemorrhagic strokes include intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH).

    • In brain bleeds, expansion and raised ICP are critical concerns; signs of herniation include pupil changes, severe headache, vomiting, and decreasing consciousness.

    • Barriers to ICP increase: fixed skull, brain tissue swelling, restricted CSF flow; management aims to prevent brain herniation and maintain perfusion.

    • Elevating the head of the bed (to about 30 degrees) and keeping the patient midline helps venous drainage and ICP control; avoid sudden neck flexion or head turning that could impede drainage.

    • Invasive procedures (surgery, clipping, coiling for aneurysms) come with high risk; decisions are individualized.

  • Special topics and real-world practice pointers

    • Atrial fibrillation and PFO considerations: AF can be a source of cardioembolic strokes; PFO closure may be considered in select patients to reduce recurrent stroke risk.

    • Endarterectomy vs stenting: carotid interventions to reduce stroke risk vary by patient anatomy and comorbidity; risk of peri-procedural stroke exists.

    • Lipids and lifestyle: LDL reductions and HDL increases (e.g., via exercise) are important for long-term vascular health; the Mediterranean diet is emphasized.

    • TED hose vs SCDs for DVT prophylaxis in stroke patients: practice varies; SCDs are increasingly used in many settings; TED hose may be considered in some contexts.

    • NIH Stroke Scale (NIHSS) practical use: helps quantify stroke severity and track progress; not all elements must be perfect to document a deficit; focus on interactions and comprehension as well as motor signs.

    • Individualized patient education: stroke education should be tailored to the patient; avoid dumping information; provide actionable guidance and follow-up plans.

  • Practical tips for exam scenarios and clinical reasoning

    • Anchor on anatomy to reason through symptoms: if a stroke affects the left hemisphere, expect language deficits in a typical right-handed patient; if the right hemisphere, watch for neglect and emotional/impulse control changes.

    • Distinguish coordination vs weakness: dysarthria is a coordination issue (cerebellar or bulbar) rather than a primary motor weakness; true limb weakness points to motor cortex/frontal lobe involvement.

    • Aphasia testing requires both comprehension and expression checks; Wernicke’s aphasia makes following commands hard, Broca’s makes word production hard but comprehension may be preserved.

    • When assessing a patient with suspected stroke, prioritize time-sensitive decisions (thrombolysis eligibility, thrombectomy window) while continuing to collect imaging and clinical data.

    • If a patient cannot communicate well (aphasia or cognitive impairment), use open-ended questions, nonverbal cues, and visual instructions to gauge understanding and cooperation.

  • Quick recap of core ideas

    • TIAs are warning signals; most TIAs portend a stroke within days to weeks if risk factors aren’t controlled.

    • Ischemic strokes are most common; hemorrhagic strokes require rapid identification and different management.

    • Localization of deficits helps infer the brain areas involved and guides management.

    • Time is brain: reperfusion therapies (tPA/TNK and thrombectomy) rely on rapid imaging and decision-making.

    • Imaging and physiology (diffusion/perfusion, CTA/MRI) inform treatment windows and strategies.

    • Post-stroke care is multidisciplinary: BP control, glycemic control, lipid management, prevention of secondary injury, rehabilitation, and psychosocial support are essential for recovery.

  • Notes on terminology and context from the transcript

    • ABCD2 score and CHADS2 score were referenced as practical risk tools; the exact scoring rules follow standard medical guidelines.

    • TNK (tenecteplase) was highlighted as a faster, single-bolus alternative to alteplase (rt-PA) in specific clinical scenarios.

    • There was emphasis on “time vs tissue” and that the brain’s penumbra is salvageable tissue that we want to save; the dead core cannot be revived.

    • The speech-language and NIH exam content was described in practical, bedside terms to guide nursing and student performance.

  • Ethical and practical implications

    • Early and accurate stroke recognition saves lives and reduces disability.

    • Individualized care plans respect patient preferences and quality of life while balancing risks of therapies.

    • Communication with patients and families about prognosis, treatment options, and potential side effects is essential.

    • Ongoing education for clinicians and nursing staff improves outcomes, particularly in high-stress acute settings.

  • Quick reference formulas and numbers (LaTeX)

    • ABCD2 score components:

    • A = Age ≥ 60 → 1

    • B = Blood pressure at presentation ≥ 140/90 mmHg → 1

    • C = Clinical features: unilateral weakness → 2; speech impairment without weakness → 1

    • D = Duration: ≥ 60 minutes → 2; 10–59 minutes → 1

    • DM = Diabetes mellitus → 1

    • ABCD2=A+B+C+D+DM<br>ABCD_2 = A + B + C + D + DM <br>

    • CHADS2 score components (for AF-related stroke risk):

    • CHF, Hypertension, Age ≥ 75, Diabetes, Stroke/TTIA (2 points)

    • CHADS2=extCHF+extHTN+2imesextStroke/TIA+extDiabetes+extAge75CHADS_2 = ext{CHF} + ext{HTN} + 2 imes ext{Stroke/TIA} + ext{Diabetes} + ext{Age≥75}

    • Thrombolysis pharmacology (general reference):

    • Alteplase (rt-PA): extDose=0.9racmgkgext(max90extmg)ext{Dose} = 0.9 rac{mg}{kg} ext{ (max }90 ext{ mg)} with 10% given as bolus and 90% infused over 60 minutes.

    • Tenecteplase (TNK): typically a single bolus of 0.25racmgkgext(max 25mg)0.25 rac{mg}{kg} ext{ (max ~25 mg)}.

:title Stroke and TIA: Comprehensive Study Notes

Note: These notes condense and organize the content from the provided transcript into a study-friendly form. They include major ideas, nuances, and practical points mentioned during the lecture, with key definitions and formulas presented in LaTeX where appropriate.